|
|
| A Sustainable Future: Phasing Out Animal Testing | Application Note | MilliporeSigma | Discover a practical roadmap for replacing animal tests with advanced molecular methods, as well as how regulatory updates and innovative technologies are shaping a sustainable future. |
|
|
|
|
By Kieran Falvey, Pharmalliance Consulting Ltd. | EU GMP Annex 1 mandates a documented contamination control strategy, and FDA expectations are substantively equivalent. Let's look at why CDMOs are disproportionately exposed. | |
|
|
|
A conversation between Gourav Pandey, Takeda, and Life Science Connect's Jon O'Connell | A Takeda quality executive demonstrates how a team of AI agents uses synthetic data to provide decision support ahead of CDMO audits. | |
|
|
|
By John W.M. Claud, Nelson Mullins Riley & Scarborough | FDA's complementary pilot could help weed through a persistent examination backlog, but uncertainty and upheaval in leadership at the top puts its future in question. | |
|
|
